Current molecular imaging of spinal tumors in clinical practice.

摘要: Energy metabolism measurements in spinal cord tumors, as well In osseous tumors/metastasis vivo, are rarely performed only with molecular imaging (MI) by positron emission tomography (PET). This modality developed from a small number of basic clinical science investigations followed subsequent work that influenced and enhanced the research others. Apart precise anatomical localization coregistration morphological quantification, most intriguing advantage this is opportunity to investigate time course (dynamics) disease-specific events intact organism. Most importantly, MI represents one key technologies translational neuroscience research, helping develop experimental protocols may later be applied human patients. PET help monitor patient at vertebral level after surgery during adjuvant treatment for recurrent or progressive disease. Common indications primary secondary CNS tumors are: (i) tumor diagnosis, (ii) identification metabolically active compartments (differentiation viable tissue necrosis) (iii) prediction response measurement perfusion ischemia. While has been used under specific circumstances, question remains whether magnitude biochemical alterations observed general (specifically tumors) can reveal any prognostic value respect survival. able better identify early disease differentiate benign malignant lesions than more traditional methods. Moreover, an adequate effectiveness influence management. probes could image function targets without disturbing them modify target’s function. therefore closes gap between vitro vivo integrative biology At level, detect progression recurrence metastatic surgical treatment. cases nonsurgical treatments such chemo-, hormone- radiotherapy, it assess biological efficiency conventional modalities coupled blood markers. fact, provides unique possibility correlate topography metabolic activity, but requires additional experience find new tumors.